←Psychosis
Study register · detail Genetische Korrelationsstudie (GWAS, Mendelian Randomization) · Psychosis · 2025

The genetic relationship between cannabis use disorder, cannabis use and psychiatric disorders

Galimberti et al. ·Nature Mental Health Impact 5.8
No direction reported 4 citations
Sample—
ControlGenetic variants for psychiatric disorders…
DesignGenetische Korrelationsstudie (GWAS, Mendelian Randomization)
Summary

Genome-wide association study on cannabis use disorder (CanUD), cannabis use and psychiatric disorders; CHRNA2 variant significantly shared between CanUD and schizophrenia (colocalization + local genetic correlation); Mendelian Randomization shows bidirectional causal relationship between CanUD and most psychiatric disorders, unlike pure cannabis use.

P
PopulationAdults with cannabis use and cannabis use disorder (CanUD), GWAS cohorts with overlap to psychiatric disorders (MDD, SCZ, BPD, ADHD, AN, anxiety, PTSD), pooled n not explicitly reported
I
InterventionGenetic variants as instrumental variables for CanUD and cannabis use (Mendelian Randomization)
C
ControlGenetic variants for psychiatric disorders (MDD, SCZ, BPD, ADHD, AN, PTSD, anxiety) as exposure or outcome
O
OutcomeCanUD shows bidirectional causal relationships with almost all psychiatric disorders (strongest effect on SCZ: β=0.688±0.076, p=2.0×10⁻¹⁹; on ADHD: β=0.468±0.042, p=2.9×10⁻²⁹). Cannabis use shows only a causal relationship with ADHD (β=0.306±0.066, p=3.9×10⁻⁶). Colocalization of a CHRNA2 variant between CanUD and SCZ.
Quality profile
Sample size —
Blinding —
Effect size —
Citations / year ★★★★★
Authors
Galimberti M, Overstreet C, Gupta P, Beck S, Dao C, Deak JD, Zhou H, Johnson EC, Agrawal A, Stein MB, Levey DF, Gelernter J
DOI 10.1038/s44220-025-00440-4↗
Design: Genetische Korrelationsstudie (GWAS, Mendelian Randomization)
Share
Indication
Further studies on Psychosis
All studies →
S Belvederi Murri et al. · 2025 · Neuroscience & Biobehavioral Reviews
3 citations
The association between cannabis use and paranoia: Meta-analysis of experimental and observational studies
Clear benefit Meta-Analyse (Bayesian Model-Averaged)

Bayesian Meta-Analyse über k=13 Studien (n=13.559) zu Cannabis und paranoiden Symptomen; experimentelle Studien (k=5): Cannabinoid-Teilnehmer entwickelten schwerere paranoide Symptome als Placebo (SMD=0.47, 95% CI 0.13–0.48, PPI=94%); Querschnittsstudien (k=4): Cannabis-User höhere Odds für Paranoia (OR=1.75, 95% CI 1.43–2.07, PPI=99%); prospektive Studien (k=3) zeigen Assoziation mit späterem Paranoia-Onset.

10.1016/j.neubiorev.2025.106269 View study →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

n=79 RCTs (n=6.462), umfassende SR zu medizinischem Cannabis; identifiziert psychotische Symptome als häufige Nebenwirkung (moderate Evidenz), keine therapeutische Evidenz für Psychose-Behandlung; relevante Sicherheitsdaten.

10.1001/jama.2015.6358 View study →
A Wilson et al. · 2026 · The lancet. Psychiatry
3 citations
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis.
Mixed Meta-Analyse

Systematische Review + Meta-Analyse zu Cannabinoiden bei psychischen Störungen und Substanzstörungen; k=54 RCTs (n=2.477, 69% männlich, medianes Alter 33,3 Jahre). 44% der Studien mit hohem Bias-Risiko, Evidenzqualität meist niedrig. CBD+THC-Kombination reduzierte Cannabis-Entzugssymptome (SMD=-0.29, 95% CI -0.57 bis -0.02) und wöchentlichen Cannabis-Konsum (-1.00g, 95% CI -1.69 bis [Daten unvollständig im Abstract]).

10.1016/s2215-0366(26)00015-5 View study →

The impediment to action advances action. — Marcus Aurelius